Related references
Note: Only part of the references are listed.Migraine
Michel D. Ferrari et al.
NATURE REVIEWS DISEASE PRIMERS (2022)
Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database
Alexandre O. Gerard et al.
JOURNAL OF HEADACHE AND PAIN (2022)
Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis
Diane Merino et al.
BIOMEDICINES (2022)
New Oral Drugs for Migraine
Nazia Karsan et al.
CNS DRUGS (2022)
Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
Kerry Knievel et al.
CEPHALALGIA (2020)
Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study
Darren Wilbraham et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system
Alejandro Labastida-Ramirez et al.
PAIN (2020)
Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls
Eric M. Pearlman et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2020)
Lasmiditan mechanism of action - review of a selective 5-HT1Fagonist
David B. Clemow et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis
Min Hou et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review
Elizabeth Leroux et al.
ADVANCES IN THERAPY (2020)
Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019
T. J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
Peter J. Goadsby et al.
BRAIN (2019)
Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN
John H. Krege et al.
CEPHALALGIA (2019)
Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk
Paul G. Mathew et al.
HEADACHE (2019)
Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan
Eloisa Rubio-Beltran et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials
Robert E. Shapiro et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Migraine and the trigeminovascular system-40 years and counting
Messoud Ashina et al.
LANCET NEUROLOGY (2019)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?
Eloisa Rubio-Beltran et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Lasmiditan is an effective acute treatment for migraine A phase 3 randomized study
Bernice Kuca et al.
NEUROLOGY (2018)
Aura and Other Neurologic Dysfunction in or with Migraine
Narayan R. Kissoon et al.
HEADACHE (2017)
The Journey of the Non-Vascular Relief for Migraine: From 'Triptans' To 'Ditans'
Alphienes S. Xavier et al.
CURRENT CLINICAL PHARMACOLOGY (2017)
Migraine and its psychiatric comorbidities
Mia Tova Minen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
On visual hallucinations and cortical networks: a trans-diagnostic review
Rowena Carter et al.
JOURNAL OF NEUROLOGY (2015)
Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies
G. Roberto et al.
CEPHALALGIA (2015)
The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine
Uwe Reuter et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain
Rodrigo Noseda et al.
PAIN (2013)
Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study
Markus Farkkila et al.
LANCET NEUROLOGY (2012)
Migraine and psychiatric comorbidity: a review of clinical findings
Fabio Antonaci et al.
JOURNAL OF HEADACHE AND PAIN (2011)
Preclinical pharmacological profile of the selective 5-HTIF receptor agonist lasmiditan
David L. Nelson et al.
CEPHALALGIA (2010)
Migraine and psychiatric disorders: comorbidities, mechanisms, and clinical applications
S. M. Baskin et al.
NEUROLOGICAL SCIENCES (2009)
Quantitative signal detection using spontaneous ADR reporting
A. Bate et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Treatment-emergent CNS symptoms following triptan therapy are part of the attack
P. J. Goadsby et al.
CEPHALALGIA (2007)
Under-reporting of adverse drug reactions - A systematic review
Lorna Hazell et al.
DRUG SAFETY (2006)
Psychiatric comorbidity in migraine: a review
F Radat et al.
CEPHALALGIA (2005)
[3H]LY334370, a novel radioligand for the 5-HT1F receptor.: II.: Autoradiographic localization in rat, guinea pig, monkey and human brain
VL Lucaites et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2005)
Consensus statement:: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine
D Dodick et al.
HEADACHE (2004)
Replication of the weber effect using postmarketing adverse event reports voluntarily submitted to the United States food and drug administration
NR Hartnell et al.
PHARMACOTHERAPY (2004)
Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein
DC Evans et al.
DRUG METABOLISM AND DISPOSITION (2003)
Mechanisms of action of the 5-HT1B/1D receptor agonists
SJ Tepper et al.
ARCHIVES OF NEUROLOGY (2002)
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
EP van Puijenbroek et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2002)
Temporal patterns of NSAID spontaneous adverse event reports - The Weber effect revisited
EJ Wallenstein et al.
DRUG SAFETY (2001)
Headache and major depression - Is the association specific to migraine?
N Breslau et al.
NEUROLOGY (2000)
Share Paper
